FDA approves Dupixent to treat adolescents with atopic dermatitis
The FDA has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Comment: Dupixent, is the first and only biologic to show positive results as monotherapy in adolescents aged 12 to 17 years with inadequately controlled disease.
Visit our Atopic Dermatitis learning zone for more information and resources.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.